Clinical Trial Update: Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated whether antagonism of growth hormone signaling could improve insulin sensitivity in adults with pre-diabetes and metabolic sy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Insulin Resistance
• Metabolic Syndrome

Drugs mentioned

• Growth hormone antagonist (growth hormone receptor antagonist)

Snippet

Sponsor: University of California, San Francisco | Conditions: Diabetes, Metabolic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2017-03-13